Maryland Caps Prices on Jardiance and Ozempic

State board approves first-in-nation upper payment limits on two diabetes drugs, effective January 2027.

Updated on Nov. 17, 2026 in Diabetes

Isometric editorial illustration of a tall stack of smooth white capsule forms cut by a single horizontal line on a pale field, suggesting a capped payment limit.
Maryland's Prescription Drug Affordability Board unanimously approved first-in-nation upper payment limits on Jardiance and Ozempic, effective January 2027. AI Illustration. Upload story photo >

Live Poll

Do you think government limits on prescription drug prices will lower what you pay?

The Maryland Prescription Drug Affordability Board unanimously approved final regulations setting upper payment limits on Jardiance and Ozempic. The limits are the first of their kind on prescription drugs in the nation.

Why it matters

The limits target what state and local governments pay for certain prescription drugs, with participating health plans receiving supplemental rebates when net spending exceeds the state-set caps. Because most participating plans already charge flat copays, the savings are expected to flow mainly to government health plans rather than patients.

The Maryland board projects the limits will save government health plans $6.1 million annually, based on estimated net costs after discounts and rebates. The projection does not address how much of the savings, if any, will reach individual patients, and actual results will not be known until the limits take effect in 2027.

The players

Maryland Prescription Drug Affordability Board

A state body created in 2019 to review and set limits on prescription drug costs for Maryland's public health plans.

Boehringer Ingelheim

A German pharmaceutical company that manufactures Jardiance, a medication used in the treatment of type 2 diabetes.

Novo Nordisk

A Danish pharmaceutical company that manufactures Ozempic, a widely prescribed diabetes medication that is also used for weight management.

The details

Participation is voluntary for eligible state and local government entities during the first year, and becomes mandatory for entities that opt in beginning January 1, 2028. The limits apply to Jardiance, made by Boehringer Ingelheim, and Ozempic, made by Novo Nordisk, but do not apply to Wegovy.

Timeline

  1. 2019: Maryland created its prescription drug affordability board.

  2. November 16, 2026: The board voted unanimously to approve the Jardiance and Ozempic limits.

  3. January 1, 2027: Upper payment limits take effect and voluntary participation begins.

  4. January 1, 2028: Participation becomes mandatory for entities that opt in.

Health Landscape

The approval marks the first concrete use of the authority Maryland gave its prescription drug affordability board in 2019, shifting the state from review to enforceable payment ceilings. It places Maryland among the earliest states to test direct price caps on widely prescribed diabetes and weight-management drugs.

Because the projected savings are expected to flow mainly to government health plans, patients may not see lower out-of-pocket costs from the limits. Residents covered by Maryland's public plans should check with their plan administrator to learn whether and how the caps affect their prescriptions.

The takeaway

State-level price caps on diabetes drugs are moving from proposal to practice, but their benefit to patients depends on how savings are passed through to plan members. Readers with diabetes coverage through public plans should watch how their plans respond before the 2027 start date.

What happens next

The payment limits take effect January 1, 2027, and participation becomes mandatory for opt-in entities on January 1, 2028.

Further reading

For related coverage, explore the latest reporting in our Diabetes section.

Live Poll

Do you think government limits on prescription drug prices will lower what you pay?